Research Articles

Design, Synthesis and biological evaluation of diazeno-thiazole derivatives as ribonucleotide reductase inhibitors

1,217 Views362 Downloads3 Citations

PDF

Abstract

Ribonucleotide reductase(RNR) is a metalloenzyme that catalyses the rate limiting step in DNA synthesis and repair. It causes the reduction of ribonucleotide to 2’-deoxyribonuclotides which are used as precursors for DNA synthesis, thus offering a good target for inhibition of cell synthesis. Experimental results have been proven that RNR inhibitors can be used as antiviral, anticancer or antibacterial agents. Here we report the synthesis of a novel class of diazeno-thiazole derivatives as potent RNR inhibitors. A series of forty molecules were synthesized and evaluated for their RNR inhibitory properties. All compounds were found to be good inhibitors of the RNR. Compound 3iwas found to be most active showing an IC50 value of 0.8 µm. The established SAR study indicated the presence of a polar bridge with an adjacent flexible aromatic ringprerequisite for RNR inhibitory activity. Moreover, compounds having an additional 4-chloro phenyl ring were found to be most potent.

References

  1. Graslund, A.; Sahlin, M. Electron paramagnetic resonance and nuclear magnetic resonance studies of class I ribonucleotide reductase. Annu Rev Biophys Biomol Struct 1996, 25 (1), 259-286.
  2. https://doi.org/10.1146/annurev.bb.25.060196.001355 DOI: https://doi.org/10.1146/annurev.bb.25.060196.001355
  3. Reichard, P.; Ehrenberg, A. Ribonucleotide reductase--a radical enzyme. Science 1983, 221 (4610), 514-519.
  4. https://doi.org/10.1126/science.6306767 DOI: https://doi.org/10.1126/science.6306767
  5. Gräslund, A.; Ehrenberg, A. Tyrosyl radical, diiron center and enzyme mechanism in ribonucleotide reductase. Appl Magn Reson 2007, 31 (3), 447-455.
  6. https://doi.org/10.1007/BF03166595 DOI: https://doi.org/10.1007/BF03166595
  7. Herrick, J.; Sclavi, B. Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage. Mol Microbiol 2007, 63 (1), 22-34.
  8. https://doi.org/10.1111/j.1365-2958.2006.05493.x DOI: https://doi.org/10.1111/j.1365-2958.2006.05493.x
  9. Nordlund, P.; Reichard, P. Ribonucleotide reductases. Annu Rev Biochem 2006, 75, 681-706.
  10. https://doi.org/10.1146/annurev.biochem.75.103004.142443 DOI: https://doi.org/10.1146/annurev.biochem.75.103004.142443
  11. Jordan, A.; Reichard, P. Ribonucleotide reductases. Annu Rev Biochem 1998, 67 (1), 71-98.
  12. https://doi.org/10.1146/annurev.biochem.67.1.71 DOI: https://doi.org/10.1146/annurev.biochem.67.1.71
  13. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006, 6 (5), 409-431.
  14. https://doi.org/10.2174/156800906777723949 DOI: https://doi.org/10.2174/156800906777723949
  15. Seiwert, T. Y.; Haraf, D. J.; Cohen, E. E.; Stenson, K.; Witt, M. E.; Dekker, A.; Kocherginsky, M.; Weichselbaum, R. R.; Chen, H. X.; Vokes, E. E. Phase I study of bevacizumab added to fluorouracil-and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008, 26 (10), 1732-1741.
  16. https://doi.org/10.1200/JCO.2007.13.1706 DOI: https://doi.org/10.1200/JCO.2007.13.1706
  17. SHN Moorthy, N.; MFSA Cerqueira, N.; J Ramos, M.; A Fernandes, P. Development of ribonucleotide reductase inhibitors: a review on structure activity relationships. Mini Rev Med Chem 2013, 13 (13), 1862-1872.
  18. https://doi.org/10.2174/13895575113136660090 DOI: https://doi.org/10.2174/13895575113136660090
  19. Nutting, C.; Van Herpen, C.; Miah, A.; Bhide, S.; Machiels, J.-P.; Buter, J.; Kelly, C.; De Raucourt, D.; Harrington, K. Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol 2009, mdn775.
  20. https://doi.org/10.1093/annonc/mdn775 DOI: https://doi.org/10.1093/annonc/mdn775
  21. Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.; Wang, L. Z.; Mo, F.; Chan, A. T.; Zee, B. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 2008, 26 (2), 169-173.
  22. https://doi.org/10.1007/s10637-007-9085-0 DOI: https://doi.org/10.1007/s10637-007-9085-0
  23. Cerqueira, N. M.; Pereira, S.; Fernandes, P. A.; Ramos, M. J. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem 2005, 12 (11), 1283-1294.
  24. https://doi.org/10.2174/0929867054020981 DOI: https://doi.org/10.2174/0929867054020981
  25. Jadav, S. S.; Kaptein, S.; Timiri, A.; De Burghgraeve, T.; Badavath, V. N.; Ganesan, R.; Sinha, B. N.; Neyts, J.; Leyssen, P.; Jayaprakash, V. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors. Biorg Med Chem Lett 2015, 25 (8), 1747-1752
  26. https://doi.org/10.1016/j.bmcl.2015.02.059 DOI: https://doi.org/10.1016/j.bmcl.2015.02.059

Author information

Rights and permissions

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

About this article

Cite this article

(1)
Mohd Siddique, M. U.; Jadav, S. S.; Graser, G.; Saiko, P.; Szekeres, T.; Sinha, B. N.; Jayaprakash, V. Design, Synthesis and Biological Evaluation of Diazeno-Thiazole Derivatives As Ribonucleotide Reductase Inhibitors. J Pharm Chem 2017, 4 (2), 20-24. https://doi.org/10.14805/jphchem.2017.art77.
Received
March 22, 2017
Published
May 25, 2017
Section
Research Articles
Pages
20-24

Keywords

Most read articles by the same author(s)

<< < 1 2